Aankondiging • Jul 24
Albert David Limited to Report Q1, 2027 Results on Aug 06, 2026 Albert David Limited announced that they will report Q1, 2027 results on Aug 06, 2026 Upcoming Dividend • Jul 23
Upcoming dividend of ₹5.00 per share Eligible shareholders must have bought the stock before 30 July 2026. Payment date: 05 September 2026. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.4%). In line with average of industry peers (0.7%). Reported Earnings • Jul 15
Full year 2026 earnings released: ₹2.62 loss per share (vs ₹30.14 profit in FY 2025) Full year 2026 results: ₹2.62 loss per share (down from ₹30.14 profit in FY 2025). Revenue: ₹3.34b (down 3.5% from FY 2025). Net loss: ₹14.9m (down 109% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Declared Dividend • May 14
Dividend of ₹5.00 announced Dividend of ₹5.00 is the same as last year. Ex-date: 30th July 2026 Payment date: 5th September 2026 Dividend yield will be 0.7%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months and having no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. Reported Earnings • May 14
Full year 2026 earnings released: ₹2.62 loss per share (vs ₹30.14 profit in FY 2025) Full year 2026 results: ₹2.62 loss per share (down from ₹30.14 profit in FY 2025). Revenue: ₹3.41b (down 1.4% from FY 2025). Net loss: ₹14.9m (down 109% from profit in FY 2025). Over the last 3 years on average, earnings per share has fallen by 59% per year but the company’s share price has increased by 5% per year, which means it is well ahead of earnings. Aankondiging • May 04
Albert David Limited to Report Q4, 2026 Results on May 12, 2026 Albert David Limited announced that they will report Q4, 2026 results on May 12, 2026 Reported Earnings • Feb 14
Third quarter 2026 earnings released: EPS: ₹26.81 (vs ₹16.45 loss in 3Q 2025) Third quarter 2026 results: EPS: ₹26.81 (up from ₹16.45 loss in 3Q 2025). Revenue: ₹1.02b (up 23% from 3Q 2025). Net income: ₹153.0m (up ₹246.9m from 3Q 2025). Profit margin: 15% (up from net loss in 3Q 2025). Over the last 3 years on average, earnings per share has fallen by 41% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. Aankondiging • Feb 02
Albert David Limited to Report Q3, 2026 Results on Feb 11, 2026 Albert David Limited announced that they will report Q3, 2026 results on Feb 11, 2026 Reported Earnings • Nov 14
Second quarter 2026 earnings released: ₹5.79 loss per share (vs ₹31.67 profit in 2Q 2025) Second quarter 2026 results: ₹5.79 loss per share (down from ₹31.67 profit in 2Q 2025). Revenue: ₹851.0m (down 14% from 2Q 2025). Net loss: ₹33.0m (down 118% from profit in 2Q 2025). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 11% per year, which means it is well ahead of earnings. Aankondiging • Nov 03
Albert David Limited to Report Q2, 2026 Results on Nov 12, 2025 Albert David Limited announced that they will report Q2, 2026 results on Nov 12, 2025 Aankondiging • Jul 25
Albert David Limited to Report Q1, 2026 Results on Aug 02, 2025 Albert David Limited announced that they will report Q1, 2026 results at 12:15 PM, Indian Standard Time on Aug 02, 2025 Upcoming Dividend • Jul 18
Upcoming dividend of ₹5.00 per share Eligible shareholders must have bought the stock before 25 July 2025. Payment date: 07 August 2025. Payout ratio is a comfortable 17% but the company is not cash flow positive. Trailing yield: 0.5%. Lower than top quartile of Indian dividend payers (1.2%). Lower than average of industry peers (0.8%). Reported Earnings • Jul 10
Full year 2025 earnings released: EPS: ₹30.14 (vs ₹132 in FY 2024) Full year 2025 results: EPS: ₹30.14 (down from ₹132 in FY 2024). Revenue: ₹3.46b (down 4.6% from FY 2024). Net income: ₹172.0m (down 77% from FY 2024). Profit margin: 5.0% (down from 21% in FY 2024). Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 16% per year. Declared Dividend • May 15
Dividend reduced to ₹5.00 Dividend of ₹5.00 is 57% lower than last year. Ex-date: 25th July 2025 Payment date: 1st September 2025 Dividend yield will be 0.6%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is covered by earnings (9% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 8.7% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to decline by 90% to shift the payout ratio to a potentially unsustainable range, which is more than the 2.1% EPS decline seen over the last 5 years. Reported Earnings • May 14
Full year 2025 earnings released: EPS: ₹30.14 (vs ₹132 in FY 2024) Full year 2025 results: EPS: ₹30.14 (down from ₹132 in FY 2024). Revenue: ₹3.75b (up 3.6% from FY 2024). Net income: ₹172.0m (down 77% from FY 2024). Profit margin: 4.6% (down from 21% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 13% per year whereas the company’s share price has increased by 15% per year. New Risk • May 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (9.0% average weekly change). Profit margins are more than 30% lower than last year (11% net profit margin). Market cap is less than US$100m (₹5.14b market cap, or US$60.5m). Aankondiging • Mar 10
Albert David Limited Announces Resignation of Shirish Gundopant Belapure as Independent Director Albert David Limited announced that Mr. Shirish Gundopant Belapure has tendered his resignation as an Independent Director of the company, with effect from March 10, 2025. Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to ₹885, the stock trades at a trailing P/E ratio of 12.4x. Average trailing P/E is 28x in the Pharmaceuticals industry in India. Total returns to shareholders of 69% over the past three years. Reported Earnings • Feb 13
Third quarter 2025 earnings released: ₹16.45 loss per share (vs ₹32.80 profit in 3Q 2024) Third quarter 2025 results: ₹16.45 loss per share (down from ₹32.80 profit in 3Q 2024). Revenue: ₹740.8m (down 16% from 3Q 2024). Net loss: ₹93.9m (down 150% from profit in 3Q 2024). Over the last 3 years on average, earnings per share has increased by 25% per year but the company’s share price has only increased by 16% per year, which means it is significantly lagging earnings growth. Aankondiging • Feb 01
Albert David Limited to Report Q3, 2025 Results on Feb 12, 2025 Albert David Limited announced that they will report Q3, 2025 results at 12:15 PM, Indian Standard Time on Feb 12, 2025 Reported Earnings • Nov 17
Second quarter 2025 earnings released: EPS: ₹31.67 (vs ₹35.57 in 2Q 2024) Second quarter 2025 results: EPS: ₹31.67 (down from ₹35.57 in 2Q 2024). Revenue: ₹1.19b (up 28% from 2Q 2024). Net income: ₹180.7m (down 11% from 2Q 2024). Profit margin: 15% (down from 22% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 31% per year whereas the company’s share price has increased by 30% per year. Aankondiging • Nov 09
Albert David Limited to Report Q2, 2025 Results on Nov 14, 2024 Albert David Limited announced that they will report Q2, 2025 results on Nov 14, 2024 Buy Or Sell Opportunity • Aug 29
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 46% to ₹1,629. The fair value is estimated to be ₹1,314, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.3% over the last 3 years. Earnings per share has grown by 31%. Valuation Update With 7 Day Price Move • Aug 23
Investor sentiment improves as stock rises 24% After last week's 24% share price gain to ₹1,448, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 37x in the Pharmaceuticals industry in India. Total returns to shareholders of 163% over the past three years. Aankondiging • Aug 09
Albert David Limited Approves Dividend for the Financial Year Ended on March 31, 2024 Albert David Limited at the Annual General Meeting held on August 9, 2024 approved declaration of Dividend of INR 11.50 per equity share of INR 10 each for the financial year ended on March 31, 2024. Buy Or Sell Opportunity • Jul 29
Now 20% overvalued after recent price rise Over the last 90 days, the stock has risen 11% to ₹1,326. The fair value is estimated to be ₹1,103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 33%. Upcoming Dividend • Jul 26
Upcoming dividend of ₹11.50 per share Eligible shareholders must have bought the stock before 02 August 2024. Payment date: 08 September 2024. Payout ratio is a comfortable 8.7% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Indian dividend payers (1.1%). Higher than average of industry peers (0.7%). Reported Earnings • Jul 15
Full year 2024 earnings released: EPS: ₹132 (vs ₹63.39 in FY 2023) Full year 2024 results: EPS: ₹132 (up from ₹63.39 in FY 2023). Revenue: ₹3.62b (up 6.1% from FY 2023). Net income: ₹754.2m (up 109% from FY 2023). Profit margin: 21% (up from 11% in FY 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year whereas the company’s share price has increased by 34% per year. Buy Or Sell Opportunity • Jul 01
Now 23% overvalued after recent price rise Over the last 90 days, the stock has risen 21% to ₹1,361. The fair value is estimated to be ₹1,103, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 33%. Buy Or Sell Opportunity • Jun 21
Now 21% overvalued after recent price rise Over the last 90 days, the stock has risen 22% to ₹1,335. The fair value is estimated to be ₹1,105, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 10% over the last 3 years. Earnings per share has grown by 33%. Valuation Update With 7 Day Price Move • Jun 12
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to ₹1,269, the stock trades at a trailing P/E ratio of 9.6x. Average trailing P/E is 33x in the Pharmaceuticals industry in India. Total returns to shareholders of 156% over the past three years. Declared Dividend • May 15
Dividend of ₹11.50 announced Shareholders will receive a dividend of ₹11.50. Ex-date: 2nd August 2024 Payment date: 8th September 2024 Dividend yield will be 1.0%, which is higher than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (14% earnings payout ratio) and cash flows (15% cash payout ratio). The dividend has increased by an average of 7.2% per year over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. Earnings per share has grown by 34% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Aankondiging • May 15
Albert David Limited, Annual General Meeting, Aug 09, 2024 Albert David Limited, Annual General Meeting, Aug 09, 2024. Reported Earnings • May 14
Full year 2024 earnings released: EPS: ₹132 (vs ₹63.39 in FY 2023) Full year 2024 results: EPS: ₹132 (up from ₹63.39 in FY 2023). Revenue: ₹4.20b (up 23% from FY 2023). Net income: ₹754.2m (up 109% from FY 2023). Profit margin: 18% (up from 11% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has increased by 39% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • May 07
Albert David Limited to Report Q4, 2024 Results on May 13, 2024 Albert David Limited announced that they will report Q4, 2024 results on May 13, 2024 Aankondiging • May 06
Albert David Limited Announces Resignation of Abhishek Seth as Company Secretary & Compliance Officer, Effective May 31, 2024 Albert David Limited informed that Mr. Abhishek Seth (ACS - 39671), Company Secretary & Compliance Officer, has resigned from the services of the Company effective May 31, 2024, in view of career opportunity outside the organization. In view of the resignation, Mr. Seth will also cease to be a Key Managerial Person under the provisions of Section 203 and other applicable provisions, if any, of the Companies Act, 2013 and Regulation 30(5) of the SEBI Listing Regulations for determining materiality of events /information for disclosure to the Stock Exchanges. Aankondiging • Mar 14
Albert David Limited Announces Management Changes Albert David Limited at its board meeting held on 14 March 2024 announced that Based on the recommendation of the Nomination and Remuneration Committee of the Company, appointed Mr. Abhishek Seth (ACS-39671) as the Company Secretary & Compliance Officer, Nodal Officer (IEPF) and Chief Investor Relations Officer of the Company effective 14th March 2024 and Noted that Mr. Rajiv Singhi (DIN:00071285) and Mr. Hemal Kampani (DIN:00057715), Independent Directors of the Company, will be completing their second & final term as Independent Directors effective end of day 31st March 2024, and, thus, placed on record their appreciation for the retiring Directors. Reason for change of Mr. Abhishek Seth: In view of resignation of earlier Company Secretary & Compliance Officer-cum-Legal Head of the Company, and, based on recommendation of the Nomination and Remuneration Committee of the Company, the Board has appointed Mr. Abhishek Seth as the Company Secretary & Compliance Officer of the Company, who shall also function as the Nodal Officer (IEPF) and Chief Investor Relations Officer. Mr. Abhishek Seth is an Associate Member of the Institute of Company Secretaries of India (Membership No. 39671) and holds a Master's in Economics from University of Calcutta. He has around 9 years of post-qualification experience in the Corporate Secretarial and Compliance domain. He has been associated with Albert David Limited for nearly 8 years across Corporate Secretarial, Compliance and Finance functions. Prior to association with Albert David Limited, he was associated with Bengal Shelter Housing Development Limited as Company Secretary. Reported Earnings • Feb 06
Third quarter 2024 earnings released: EPS: ₹32.80 (vs ₹18.48 in 3Q 2023) Third quarter 2024 results: EPS: ₹32.80 (up from ₹18.48 in 3Q 2023). Revenue: ₹1.05b (up 41% from 3Q 2023). Net income: ₹187.2m (up 78% from 3Q 2023). Profit margin: 18% (up from 14% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has increased by 47% per year, which means it is tracking significantly ahead of earnings growth. Aankondiging • Jan 26
Albert David Limited to Report Q3, 2024 Results on Feb 05, 2024 Albert David Limited announced that they will report Q3, 2024 results on Feb 05, 2024 Valuation Update With 7 Day Price Move • Jan 21
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,271, the stock trades at a trailing P/E ratio of 12.5x. Average trailing P/E is 35x in the Pharmaceuticals industry in India. Total returns to shareholders of 207% over the past three years. Aankondiging • Nov 23
Albert David Limited Announces Resignation of A. B. Chakrabartty as Company Secretary and Compliance Officer Cum Legal Head of the Company Albert David Limited announced that Mr. A. B. Chakrabartty (FCS 7184) has conveyed his decision to resign from the post of Company Secretary and Compliance Officer cum Legal Head of the Company, due to career opportunity outside the organization. He will continue to discharge his duties as the Company Secretary and Compliance Officer cum Legal Head of the Company, until the close of business hours on 19 January, 2024 to facilitate smooth transition. The Company has accepted his resignation. Mr. Chakrabartty will also cease to be a Key Managerial Personnel under the provisions of Section 203 and other applicable provisions, if any of the Companies Act, 2023 and Regulation 30(5) of SEBI LODR for determining the materiality of events or transactions for making the required disclosures to the Stock Exchanges effective close of business hours on January 19, 2024. Reported Earnings • Nov 11
Second quarter 2024 earnings released: EPS: ₹35.57 (vs ₹35.29 in 2Q 2023) Second quarter 2024 results: EPS: ₹35.57 (up from ₹35.29 in 2Q 2023). Revenue: ₹1.05b (up 14% from 2Q 2023). Net income: ₹203.0m (flat on 2Q 2023). Profit margin: 19% (down from 22% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 26% per year, which means it is significantly lagging earnings growth. Aankondiging • Aug 11
Albert David Limited Approves Dividend for the Financial Year Ended March 31, 2023 Albert David Limited at its AGM held on August 10, 2023 approved dividend of INR 9.00 per equity share of INR 10.00 each for the financial year ended on 31st March, 2023. Reported Earnings • Aug 11
First quarter 2024 earnings released: EPS: ₹41.16 (vs ₹3.08 in 1Q 2023) First quarter 2024 results: EPS: ₹41.16 (up from ₹3.08 in 1Q 2023). Revenue: ₹1.10b (up 18% from 1Q 2023). Net income: ₹234.9m (up ₹217.4m from 1Q 2023). Profit margin: 21% (up from 1.9% in 1Q 2023). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 40% per year but the company’s share price has only increased by 18% per year, which means it is significantly lagging earnings growth. Aankondiging • Aug 03
Albert David Limited to Report Q1, 2024 Results on Aug 10, 2023 Albert David Limited announced that they will report Q1, 2024 results on Aug 10, 2023 Upcoming Dividend • Jul 27
Upcoming dividend of ₹9.00 per share at 1.3% yield Eligible shareholders must have bought the stock before 03 August 2023. Payment date: 09 September 2023. Payout ratio is a comfortable 14% and the cash payout ratio is 98%. Trailing yield: 1.3%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.9%). Reported Earnings • May 21
Full year 2023 earnings released: EPS: ₹63.39 (vs ₹61.78 in FY 2022) Full year 2023 results: EPS: ₹63.39 (up from ₹61.78 in FY 2022). Revenue: ₹3.57b (up 14% from FY 2022). Net income: ₹361.7m (up 2.6% from FY 2022). Profit margin: 10% (down from 11% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Aankondiging • May 13
Albert David Limited to Report Q4, 2023 Results on May 19, 2023 Albert David Limited announced that they will report Q4, 2023 results on May 19, 2023 Reported Earnings • Feb 15
Third quarter 2023 earnings released: EPS: ₹18.48 (vs ₹13.96 in 3Q 2022) Third quarter 2023 results: EPS: ₹18.48 (up from ₹13.96 in 3Q 2022). Revenue: ₹745.7m (up 4.0% from 3Q 2022). Net income: ₹105.5m (up 32% from 3Q 2022). Profit margin: 14% (up from 11% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 8% per year, which means it is significantly lagging earnings growth. Aankondiging • Feb 07
Albert David Limited to Report Q3, 2023 Results on Feb 13, 2023 Albert David Limited announced that they will report Q3, 2023 results on Feb 13, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹35.29 (vs ₹22.20 in 2Q 2022) Second quarter 2023 results: EPS: ₹35.29 (up from ₹22.20 in 2Q 2022). Revenue: ₹1.06b (up 23% from 2Q 2022). Net income: ₹201.4m (up 59% from 2Q 2022). Profit margin: 19% (up from 15% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jul 25
Upcoming dividend of ₹9.00 per share Eligible shareholders must have bought the stock before 01 August 2022. Payment date: 08 September 2022. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Indian dividend payers (1.7%). Higher than average of industry peers (1.0%). Reported Earnings • Jul 17
Full year 2022 earnings released Full year 2022 results: Revenue: ₹3.14b (up 27% from FY 2021). Net income: ₹352.6m (up 59% from FY 2021). Profit margin: 11% (up from 8.9% in FY 2021). Recent Insider Transactions • Jun 19
Executive Chairman recently bought ₹1.1m worth of stock On the 13th of June, Arun Kothari bought around 2k shares on-market at roughly ₹526 per share. In the last 3 months, they made an even bigger purchase worth ₹1.4m. Arun has been a buyer over the last 12 months, purchasing a net total of ₹7.3m worth in shares. Reported Earnings • May 13
Full year 2022 earnings released: EPS: ₹61.78 (vs ₹38.80 in FY 2021) Full year 2022 results: EPS: ₹61.78 (up from ₹38.80 in FY 2021). Revenue: ₹3.29b (up 33% from FY 2021). Net income: ₹352.6m (up 59% from FY 2021). Profit margin: 11% (up from 8.9% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has only increased by 11% per year, which means it is significantly lagging earnings growth. Board Change • Apr 27
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non-Executive Independent Director Monjori Mitra was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Apr 02
Executive Chairman recently bought ₹536k worth of stock On the 30th of March, Arun Kothari bought around 1k shares on-market at roughly ₹536 per share. In the last 3 months, they made an even bigger purchase worth ₹2.0m. Arun has been a buyer over the last 12 months, purchasing a net total of ₹4.6m worth in shares. Board Change • Apr 01
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non-Executive Independent Director Monjori Mitra was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Recent Insider Transactions • Mar 16
Executive Chairman recently bought ₹1.6m worth of stock On the 9th of March, Arun Kothari bought around 3k shares on-market at roughly ₹521 per share. In the last 3 months, they made an even bigger purchase worth ₹2.0m. Arun has been a buyer over the last 12 months, purchasing a net total of ₹3.7m worth in shares. Board Change • Mar 02
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 4 highly experienced directors. Additional Non-Executive Independent Director Monjori Mitra was the last director to join the board, commencing their role in 2020. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 17
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹13.96 (up from ₹10.72 in 3Q 2021). Revenue: ₹777.3m (up 19% from 3Q 2021). Net income: ₹79.7m (up 30% from 3Q 2021). Profit margin: 10% (in line with 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has only increased by 14% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jan 03
Investor sentiment improved over the past week After last week's 15% share price gain to ₹673, the stock trades at a trailing P/E ratio of 9.4x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 72% over the past three years. Reported Earnings • Nov 16
Second quarter 2022 earnings released: EPS ₹22.20 (vs ₹17.16 in 2Q 2021) The company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2022 results: Revenue: ₹863.4m (up 20% from 2Q 2021). Net income: ₹126.7m (up 29% from 2Q 2021). Profit margin: 15% (in line with 2Q 2021). Over the last 3 years on average, earnings per share has increased by 11% per year whereas the company’s share price has increased by 14% per year. Upcoming Dividend • Aug 30
Upcoming dividend of ₹6.00 per share Eligible shareholders must have bought the stock before 06 September 2021. Payment date: 14 October 2021. Trailing yield: 1.0%. Lower than top quartile of Indian dividend payers (1.5%). Higher than average of industry peers (0.8%). Reported Earnings • Aug 18
First quarter 2022 earnings released: EPS ₹18.30 (vs ₹7.65 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹861.5m (up 37% from 1Q 2021). Net income: ₹104.5m (up 139% from 1Q 2021). Profit margin: 12% (up from 7.0% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year. Valuation Update With 7 Day Price Move • Aug 12
Investor sentiment improved over the past week After last week's 16% share price gain to ₹612, the stock trades at a trailing P/E ratio of 15x. Average trailing P/E is 26x in the Pharmaceuticals industry in India. Total returns to shareholders of 13% over the past three years. Reported Earnings • Jun 20
Full year 2021 earnings released: EPS ₹38.80 (vs ₹33.59 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: ₹2.47b (down 23% from FY 2020). Net income: ₹221.4m (up 16% from FY 2020). Profit margin: 8.9% (up from 6.0% in FY 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Recent Insider Transactions • Apr 04
Insider recently bought ₹189k worth of stock On the 30th of March, Anand Kothari bought around 500 shares on-market at roughly ₹379 per share. In the last 3 months, there was an even bigger purchase from another insider worth ₹199k. Insiders have collectively bought ₹389k more in shares than they have sold in the last 12 months. Recent Insider Transactions • Mar 31
Executive Chairman recently bought ₹199k worth of stock On the 22nd of March, Arun Kothari bought around 500 shares on-market at roughly ₹398 per share. This was the largest purchase by an insider in the last 3 months. This was Arun's only on-market trade for the last 12 months. Is New 90 Day High Low • Feb 17
New 90-day low: ₹405 The company is down 2.0% from its price of ₹411 on 19 November 2020. The Indian market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 11% over the same period. Reported Earnings • Feb 10
Third quarter 2021 earnings released: EPS ₹10.72 (vs ₹9.20 in 3Q 2020) The company reported a decent third quarter result with improved earnings and profit margins, although revenues were weaker. Third quarter 2021 results: Revenue: ₹701.8m (down 12% from 3Q 2020). Net income: ₹61.2m (up 17% from 3Q 2020). Profit margin: 8.7% (up from 6.6% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 3% per year whereas the company’s share price has increased by 2% per year. 
